ID   Capan-1
AC   CVCL_0237
SY   CaPan-1; CAPAN-1; Capan 1; CAPAN 1; Capan1; CAPAN1
DR   BTO; BTO:0002744
DR   CLO; CLO_0002197
DR   EFO; EFO_0002153
DR   MCCL; MCC:0000126
DR   CLDB; cl639
DR   CLDB; cl640
DR   AddexBio; C0018001/31
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0265
DR   BioGRID_ORCS_Cell_line; 844
DR   BioSample; SAMN01821543
DR   BioSample; SAMN01821620
DR   BioSample; SAMN03471999
DR   BioSample; SAMN05292467
DR   BioSample; SAMN10987884
DR   cancercelllines; CVCL_0237
DR   Cell_Model_Passport; SIDM00934
DR   CGH-DB; 162-1
DR   CGH-DB; 9269-4
DR   ChEMBL-Cells; CHEMBL3307640
DR   ChEMBL-Targets; CHEMBL614536
DR   CLS; 300143
DR   Cosmic; 724646
DR   Cosmic; 736270
DR   Cosmic; 753624
DR   Cosmic; 755302
DR   Cosmic; 808173
DR   Cosmic; 872997
DR   Cosmic; 913302
DR   Cosmic; 922252
DR   Cosmic; 923166
DR   Cosmic; 932516
DR   Cosmic; 933521
DR   Cosmic; 947395
DR   Cosmic; 948374
DR   Cosmic; 948726
DR   Cosmic; 949231
DR   Cosmic; 1006365
DR   Cosmic; 1090399
DR   Cosmic; 1108338
DR   Cosmic; 1122342
DR   Cosmic; 1198205
DR   Cosmic; 1299296
DR   Cosmic; 1320462
DR   Cosmic; 1534317
DR   Cosmic; 1571774
DR   Cosmic; 1761694
DR   Cosmic; 1995362
DR   Cosmic; 2434105
DR   Cosmic-CLP; 753624
DR   DepMap; ACH-000354
DR   DSMZ; ACC-244
DR   DSMZCellDive; ACC-244
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 753624
DR   GEO; GSM206452
DR   GEO; GSM383933
DR   GEO; GSM621902
DR   GEO; GSM784706
DR   GEO; GSM886920
DR   GEO; GSM887986
DR   GEO; GSM1024398
DR   GEO; GSM1374438
DR   GEO; GSM1374439
DR   GEO; GSM1669663
DR   IARC_TP53; 1560
DR   IGRhCellID; Capan1
DR   KCLB; 30079
DR   LiGeA; CCLE_751
DR   Lonza; 1011
DR   PharmacoDB; CAPAN1_184_2019
DR   PRIDE; PXD003198
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0237
DR   PubChem_Cell_line; CVCL_0237
DR   TOKU-E; 773
DR   Wikidata; Q54808589
RX   CelloPub=CLPUB00416;
RX   DOI=10.4172/jpb.1000057;
RX   DOI=10.4172/2324-9293.1000104;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1764370;
RX   PubMed=3518877;
RX   PubMed=6278935;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=7459858;
RX   PubMed=8026879;
RX   PubMed=8286197;
RX   PubMed=8426738;
RX   PubMed=8968085;
RX   PubMed=9331070;
RX   PubMed=10027410;
RX   PubMed=10408907;
RX   PubMed=11169957;
RX   PubMed=11668190;
RX   PubMed=12692724;
RX   PubMed=14695172;
RX   PubMed=15162061;
RX   PubMed=15367885;
RX   PubMed=16912165;
RX   PubMed=18264088;
RX   PubMed=18298655;
RX   PubMed=18380791;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20418756;
RX   PubMed=21750719;
RX   PubMed=22109279;
RX   PubMed=22460905;
RX   PubMed=25167228;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27259358;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31395879;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Part of: TCGA-110-CL cell line panel.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 923.
CC   Population: Caucasian.
CC   Doubling time: 60-80 hours (CLS=300143); ~50-100 hours (DSMZ=ACC-244); ~49 hours (PBCF).
CC   HLA typing: A*02,09; B*13,17 (CLS=300143).
CC   HLA typing: A*01:01,30:01; B*13:02,57:01; C*06:02,06:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Hemizygous (PubMed=8968085; PubMed=15162061; PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 4039; FZD10; Simple; p.Asn54Lys (c.162C>A); Zygosity=Homozygous (PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 23671; GLT6D1; Simple; p.Trp198Ter (c.593G>A); Zygosity=Heterozygous (PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 4593; GRM1; Simple; p.Tyr486Ter (c.1458C>A); Zygosity=Homozygous (PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=8026879; PubMed=8426738; PubMed=15367885; PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Glu221Ter (c.661G>T); Zygosity=Homozygous (PubMed=9331070; PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser343Ter (c.1028C>G); ClinVar=VCV000822036; Zygosity=Homozygous (PubMed=10408907; PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 25082; SMAP2; Simple; p.Ser255Ter (c.764C>G); Zygosity=Heterozygous (PubMed=21750719; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (PubMed=8026879; PubMed=8426738; PubMed=15367885; Cosmic-CLP=753624; DepMap=ACH-000354).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).
CC   Genome ancestry: African=1.95%; Native American=0.56%; East Asian, North=4.79%; East Asian, South=0.11%; South Asian=7.09%; European, North=19.06%; European, South=66.44% (PubMed=30894373).
CC   Misspelling: CANPAN-1; Cosmic=2434105.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): AddexBio=C0018001/31; ATCC=HTB-79; CLS=300143; Cosmic-CLP=753624; DSMZ=ACC-244; Technion Genomics Center BCF; KCLB=30079; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 13,14
ST   D18S51: 12
ST   D19S433: 14,15
ST   D21S11: 28,30
ST   D2S1338: 20,24
ST   D3S1358: 15
ST   D5S818: 11
ST   D7S820: 10,11
ST   D8S1179: 14,16
ST   FGA: 24
ST   Penta D: 9,13 (ATCC=HTB-79; CLS=300143; DSMZ=ACC-244; PubMed=25877200)
ST   Penta D: 9,13,14 (Technion Genomics Center BCF)
ST   Penta E: 10,12
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 16
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   40Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 45
RX   CelloPub=CLPUB00416;
RA   Oberlin L.;
RT   "Treatment of pancreatic carcinoma cell lines in vitro and vivo with a
RT   monoclonal antibody against the transferrin receptor.";
RL   Thesis VMD (2009), Justus-Liebig-Universitat Giessen, Germany.
RX   DOI=10.4172/jpb.1000057;
RA   Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T.;
RT   "The proteomic profile of pancreatic cancer cell lines corresponding
RT   to carcinogenesis and metastasis.";
RL   J. Proteomics Bioinformatics 2:1-18(2009).
RX   DOI=10.4172/2324-9293.1000104;
RA   Wagenhauser M.U., Ruckert F., Niedergethmann M., Grutzmann R.,
RA   Saeger H.-D.;
RT   "Distribution of characteristic mutations in native ductal
RT   adenocarcinoma of the pancreas and pancreatic cancer cell lines.";
RL   Cell Biol. Res. Ther. 2:1000104.1-1000104.5(2013).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=1764370; DOI=10.1038/bjc.1991.467;
RA   Barton C.M., Staddon S.L., Hughes C.M., Hall P.A., O'Sullivan C.,
RA   Kloppel G., Theis B., Russell R.C.G., Neoptolemos J., Williamson R.C.N.,
RA   Lane D.P., Lemoine N.R.;
RT   "Abnormalities of the p53 tumour suppressor gene in human pancreatic
RT   cancer.";
RL   Br. J. Cancer 64:1076-1082(1991).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=6278935;
RA   Kyriazis A.P., Kyriazis A.A., Scarpelli D.G., Fogh J., Rao M.S.,
RA   Lepera R.;
RT   "Human pancreatic adenocarcinoma line Capan-1 in tissue culture and
RT   the nude mouse: morphologic, biologic, and biochemical
RT   characteristics.";
RL   Am. J. Pathol. 106:250-260(1982).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=8026879; DOI=10.1002/ijc.2910580207;
RA   Berrozpe G., Schaeffer J., Peinado M.A., Real F.X., Perucho M.;
RT   "Comparative analysis of mutations in the p53 and K-ras genes in
RT   pancreatic cancer.";
RL   Int. J. Cancer 58:185-191(1994).
RX   PubMed=8286197; DOI=10.1038/bjc.1994.24;
RA   Lohr J.-M., Trautmann B., Gottler M., Peters S., Zauner I., Maillet B.,
RA   Kloppel G.;
RT   "Human ductal adenocarcinomas of the pancreas express extracellular
RT   matrix proteins.";
RL   Br. J. Cancer 69:144-151(1994).
RX   PubMed=8426738;
RA   Kalthoff H., Schmiegel W.H., Roeder C., Kasche D., Schmidt A., Lauer G.,
RA   Thiele H.-G., Honold G., Pantel K., Riethmuller G., Scherer E.,
RA   Maurer J., Maacke H., Deppert W.;
RT   "p53 and K-RAS alterations in pancreatic epithelial cell lesions.";
RL   Oncogene 8:289-298(1993).
RX   PubMed=8968085;
RA   Goggins M.G., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L.,
RA   Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H.,
RA   Kern S.E.;
RT   "Germline BRCA2 gene mutations in patients with apparently sporadic
RT   pancreatic carcinomas.";
RL   Cancer Res. 56:5360-5364(1996).
RX   PubMed=9331070;
RA   Teng D.H.-F., Perry W.L. III, Hogan J.K., Baumgard M.L., Bell R.,
RA   Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R.,
RA   Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R.,
RA   Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M.,
RA   Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A.,
RA   Skolnick M.H., Tavtigian S.V.;
RT   "Human mitogen-activated protein kinase kinase 4 as a candidate tumor
RT   suppressor.";
RL   Cancer Res. 57:4177-4182(1997).
RX   PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4;
RA   Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A.,
RA   Meltzer P.S., Ried T.;
RT   "Specific chromosomal aberrations and amplification of the AIB1
RT   nuclear receptor coactivator gene in pancreatic carcinomas.";
RL   Am. J. Pathol. 154:525-536(1999).
RX   PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2;
RA   Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B.,
RA   Chaloupka B., Deiss Y., Simon B., Schudy A.;
RT   "Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell
RT   lines than in primary pancreatic adenocarcinomas.";
RL   Cancer Lett. 139:43-49(1999).
RX   PubMed=11169957; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1014>3.0.CO;2-U;
RA   Wallrapp C., Hahnel S., Boeck W., Soder A., Mincheva A., Lichter P.,
RA   Leder G., Gansauge F., Sorio C., Scarpa A., Gress T.M.;
RT   "Loss of the Y chromosome is a frequent chromosomal imbalance in
RT   pancreatic cancer and allows differentiation to chronic
RT   pancreatitis.";
RL   Int. J. Cancer 91:340-344(2001).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=12692724; DOI=10.1007/s00428-003-0784-4;
RA   Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.;
RT   "A comprehensive characterization of pancreatic ductal carcinoma cell
RT   lines: towards the establishment of an in vitro research platform.";
RL   Virchows Arch. 442:444-452(2003).
RX   PubMed=14695172;
RA   Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V.,
RA   Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J.,
RA   Kern S.E., Goggins M.G., Hruban R.H.;
RT   "Highly expressed genes in pancreatic ductal adenocarcinomas: a
RT   comprehensive characterization and comparison of the transcription
RT   profiles obtained from three major technologies.";
RL   Cancer Res. 63:8614-8622(2003).
RX   PubMed=15162061; DOI=10.1159/000077512;
RA   Grigorova M., Staines J.M., Ozdag H., Caldas C., Edwards P.A.W.;
RT   "Possible causes of chromosome instability: comparison of chromosomal
RT   abnormalities in cancer cell lines with mutations in BRCA1, BRCA2,
RT   CHK2 and BUB1.";
RL   Cytogenet. Genome Res. 104:333-340(2004).
RX   PubMed=15367885; DOI=10.1097/00006676-200410000-00004;
RA   Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M.,
RA   Hirohashi S.;
RT   "Orthotopic transplantation models of pancreatic adenocarcinoma
RT   derived from cell lines and primary tumors and displaying varying
RT   metastatic activity.";
RL   Pancreas 29:193-203(2004).
RX   PubMed=16912165; DOI=10.1158/0008-5472.CAN-06-0721;
RA   Calhoun E.S., Hucl T., Gallmeier E., West K.M., Arking D.E.,
RA   Maitra A., Iacobuzio-Donahue C.A., Chakravarti A., Hruban R.H.,
RA   Kern S.E.;
RT   "Identifying allelic loss and homozygous deletions in pancreatic
RT   cancer without matched normals using high-density single-nucleotide
RT   polymorphism arrays.";
RL   Cancer Res. 66:7920-7928(2006).
RX   PubMed=18264088; DOI=10.1038/nature06548;
RA   Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R.,
RA   Levine D.A., Boyd J., Reis-Filho J.S., Ashworth A.;
RT   "Resistance to therapy caused by intragenic deletion in BRCA2.";
RL   Nature 451:1111-1115(2008).
RX   PubMed=18298655; DOI=10.1111/j.1582-4934.2008.00289.x;
RA   Pilarsky C., Ammerpohl O., Sipos B., Dahl E., Hartmann A.,
RA   Wellmann A., Braunschweig T., Lohr J.-M., Jesenofsky R., Friess H.,
RA   Wente M.N., Kristiansen G., Jahnke B., Denz A., Ruckert F.,
RA   Schackert H.K., Kloppel G., Kalthoff H., Saeger H.-D., Grutzmann R.;
RT   "Activation of Wnt signalling in stroma from pancreatic cancer
RT   identified by gene expression profiling.";
RL   J. Cell. Mol. Med. 12:2823-2835(2008).
RX   PubMed=18380791; DOI=10.1111/j.1349-7006.2008.00779.x;
RA   Suzuki A., Shibata T., Shimada Y., Murakami Y., Horii A.,
RA   Shiratori K., Hirohashi S., Inazawa J., Imoto I.;
RT   "Identification of SMURF1 as a possible target for 7q21.3-22.1
RT   amplification detected in a pancreatic cancer cell line by in-house
RT   array-based comparative genomic hybridization.";
RL   Cancer Sci. 99:986-994(2008).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20418756; DOI=10.1097/MPA.0b013e3181c15963;
RA   Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J.,
RA   Scaife C.L., Firpo M.A., Mulvihill S.J.;
RT   "Phenotype and genotype of pancreatic cancer cell lines.";
RL   Pancreas 39:425-435(2010).
RX   PubMed=21750719; DOI=10.1371/journal.pone.0021639;
RA   Barber L.J., Rosa Rosa J.M., Kozarewa I., Fenwick K., Assiotis I.,
RA   Mitsopoulos C., Sims D., Hakas J., Zvelebil M., Lord C.J.,
RA   Ashworth A.;
RT   "Comprehensive genomic analysis of a BRCA2 deficient human pancreatic
RT   cancer.";
RL   PLoS ONE 6:E21639-E21639(2011).
RX   PubMed=22109279; DOI=10.1007/s13577-011-0037-9;
RA   Ding Q., Yoshimitsu M., Kuwahata T., Maeda K., Hayashi T., Obara T.,
RA   Miyazaki Y., Matsubara S., Natsugoe S., Takao S.;
RT   "Establishment of a highly migratory subclone reveals that CD133
RT   contributes to migration and invasion through epithelial-mesenchymal
RT   transition in pancreatic cancer.";
RL   Hum. Cell 25:1-8(2012).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=25167228; DOI=10.1038/bjc.2014.475;
RA   Hamidi H., Lu M., Chau K., Anderson L., Fejzo M.S., Ginther C.,
RA   Linnartz R., Zubel A., Slamon D.J., Finn R.S.;
RT   "KRAS mutational subtype and copy number predict in vitro response of
RT   human pancreatic cancer cell lines to MEK inhibition.";
RL   Br. J. Cancer 111:1788-1801(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=27259358; DOI=10.1074/mcp.M116.058313;
RA   Humphrey E.S., Su S.-P., Nagrial A.M., Hochgrafe F., Pajic M.,
RA   Lehrbach G.M., Parton R.G., Yap A.S., Horvath L.G., Chang D.K.,
RA   Biankin A.V., Wu J.-M., Daly R.J.;
RT   "Resolution of novel pancreatic ductal adenocarcinoma subtypes by
RT   global phosphotyrosine profiling.";
RL   Mol. Cell. Proteomics 15:2671-2685(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.A.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).